Astellas, ClearPath launching vaccine newcos

Astellas Pharma Inc. (Tokyo:4502) and ClearPath Development Co. partnered to form a portfolio of asset-centric companies focused on vaccines for infectious diseases. ClearPath will house and manage each newco and will provide development expertise. Astellas will have an exclusive option to acquire the companies. ClearPath is a subsidiary of product development company RRD International LLC (Rockville, Md.). ...